Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase II Trial of BIBW 2992 in Genetically Pre-Screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations.

Next Previous
X
Search
Trial Profile

An Open Label Phase II Trial of BIBW 2992 in Genetically Pre-Screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary)
  • Indications Biliary cancer; Bladder cancer; Gallbladder cancer; Gastric cancer; Gynaecological cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 17 Aug 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Jun 2010 Planned end date changed from 1 Dec 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 05 May 2010 Trial centres updated.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top